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Marcus Conrad,2,7 and Heike Beck1
Abstract
Aims: Mitochondrial thioredoxin reductase (Txnrd2) is a central player in the control of mitochondrial hy-
drogen peroxide (H2O2) abundance by serving as a direct electron donor to the thioredoxin-peroxiredoxin axis.
In this study, we investigated the impact of targeted disruption of Txnrd2 on tumor growth. Results: Tumor
cells with a Txnrd2 deficiency failed to activate hypoxia-inducible factor-1a (Hif-1a) signaling; it rather caused
PHD2 accumulation, Hif-1a degradation and decreased vascular endothelial growth factor (VEGF) levels,
ultimately leading to reduced tumor growth and tumor vascularization. Increased c-Jun NH2-terminal Kinase
( JNK) activation proved to be the molecular link between the loss of Txnrd2, an altered mitochondrial redox
balance with compensatory upregulation of glutaredoxin-2, and elevated PHD2 expression. Innovation: Our
data provide compelling evidence for a yet-unrecognized mitochondrial Txnrd-driven, regulatory mechanism
that ultimately prevents cellular Hif-1a accumulation. In addition, simultaneous targeting of both the mito-
chondrial thioredoxin and glutathione systems was used as an efficient therapeutic approach in hindering tumor
growth. Conclusion: This work demonstrates an unexpected regulatory link between mitochondrial Txnrd and
the JNK-PHD2-Hif-1a axis, which highlights how the loss of Txnrd2 and the resulting altered mitochondrial
redox balance impairs tumor growth as well as tumor-related angiogenesis. Furthermore, it opens a new avenue
for a therapeutic approach to hinder tumor growth by the simultaneous targeting of both the mitochondrial
thioredoxin and glutathione systems. Antioxid. Redox Signal. 22, 938–950.
Introduction
During tumor growth, an increase in the levels ofintracellular reactive oxygen species (ROS) is com-
monly observed (30). However, protective enzymatic
antioxidant systems are upregulated, simultaneously (6).
Accordingly, these antioxidant systems have been sug-
gested as targets for redox-dependent anti-cancer treat-
ment (47).
In mammalian cells, the major intracellular sites for ROS
production are the mitochondria, in which leakage of elec-
trons generates superoxide that is readily dismutated by
superoxide dismutase to hydrogen peroxide (H2O2). To
maintain ROS at nonpathological levels, cells are equipped
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with highly efficient antioxidant redox networks. With regard
to mitochondrial redox homeostasis, the peroxiredoxin III
(Prx III)/mitochondrial thioredoxin (Txn2)/mitochondrial
thioredoxin reductase (Txnrd2) axis is considered the most
important H2O2-scavenging system (14, 45), as corroborated
by reverse genetics in mice: Mice lacking Prx III are viable
but show increased sensitivity to ROS-generating toxins (29);
genetic deletion of either Txn2 or Txnrd2 causes embryonic
lethal phenotypes during mid-gestation and fetal develop-
ment, respectively (10, 36).
Hypoxia is another classical hallmark of tumor growth and
metastasis (21). The individual components of hypoxic sig-
naling downstream of restricted oxygen and nutrient supply
are well established and comprise the inactivation of Hypoxia-
inducible factor prolyl hydroxylase (PHD) and subsequent
stabilization of Hypoxia-inducible factor-1a (Hif-1a), cul-
minating in increased transcription of Hif-1a target genes
(41). Via these target genes, Hif-1a is involved in a myriad of
cellular processes, including typical features favoring tumor
growth such as angiogenesis or cell proliferation (44, 53).
Interestingly, Hif-1a can also be stabilized under nonhypoxic
conditions in response to various hormones (19), growth
factors, and cytokines (23), and many of these stimuli induce
ROS production as a part of their signaling cascade. Al-
though the role of hypoxia in tumor growth is well estab-
lished, conclusive data on the contribution of cellular ROS
to hypoxic signaling are scarce and even conflicting. Pre-
viously, H2O2 was viewed as an inevitable and toxic by-
product of aerobic life due to its potentially deleterious side
effects. A number of studies, however, suggest that H2O2
plays an important role in cell signaling by regulating a di-
verse set of physiological processes (12). Previous reports
demonstrated that Hif-1a stabilization and activation of its
target genes can also be induced by exogenous H2O2 or other
oxidative stressors (4, 8, 15, 34). Furthermore, mitochondrial
ROS production has also been shown to stabilize Hif-1a (5, 20,
34), and Hif-1a DNA-binding activity appears to be sensitive
to oxidizing reagents (51). On the other hand, short pre-
exposure of cells to H2O2 selectively prevents hypoxia-
induced Hif-1a binding by preventing the accumulation of
Hif-1a protein, whereas treatment of hypoxic cell extracts with
H2O2 has no effect on Hif-1a binding (24). It appears that ROS
can interfere with the Hif-1a pathway at the level of PHDs by
oxidizing the essential co-factor ferrous iron [Fe(II)] to the in-
active ferric form [Fe(III)] (17, 38). However, to date, the precise
link between ROS and hypoxic signaling has remained elusive.
To address whether the PrxIII/Txn2/Txnrd2 axis con-
tributes to tumor growth/viability by maintaining redox ho-
meostasis and controlling hypoxic signaling, we generated
transformed cells with a targeted deficiency in the mito-
chondrial ROS-regulating enzyme Txnrd2.
In our experiments, we could show that loss of Txnrd2 in
tumor cells results in a modified cellular redox balance. This
imbalance leads to a sustained upregulation of PHD2 and
failure to stabilize Hif-1a even in response to appropriate
stimuli, ultimately culminating in the inhibition of tumor
vascularization and growth. We additionally identified c-Jun
NH2-terminal Kinase ( JNK) as a hitherto unknown partici-
pant in ROS-mediated hypoxic signaling.
Results
Transformation and characterization of Txnrd2-deficient
mouse embryonic fibroblasts
The gene targeting strategy for the disruption of Txnrd2 is
depicted in Figure 1A (10). First, mouse embryonic fibro-
blasts (MEFs) were isolated from E12.5 embryos. Geno-
typing and immunoblotting was performed to confirm the
deletion of Txnrd2 (Fig. 1B). To maintain H2O2 emission
from the mitochondria at cell-tolerable levels, Txnrd2 - / -
MEFs responded with a strong compensatory upregulation
of the mitochondria-located oxidoreductase glutaredoxin-2
(grx2) (n = 5, Fig. 1C). However, despite this compensatory
response, Txnrd2 - / - cells still displayed higher ROS levels
than wild-type (WT) cells (mean fluorescence intensity:
8.6 – 2.1 in Txnrd2 + / + vs. 25.2 – 7.6 in Txnrd2 - / - cells,
n = 10, Fig. 1D).
Immortalized MEFs were transformed by lentiviral trans-
duction of the proto-oncogene c-Myc and the oncogene Ha-
rasV12 and plated in soft agar (28). We established trans-
formed cell lines from individually picked clones. This was
deemed necessary as a basis for the in vivo tumor cell im-
plantation studies. Equal expression of c-Myc and Ha-rasV12
was confirmed by immunoblotting (Fig. 1E). Transformation
of cells did not have any impact on cellular ROS levels (mean
fluorescence intensity: 9.9 – 1.6 in Txnrd2 + / + vs. 20.7 – 4.9
in Txnrd2 - / - , n = 10, data not shown). However, we ob-
served an alignment of in vitro proliferation of the trans-
formed WT and knockout (KO) clones under baseline cell
culture conditions (n = 6, Fig. 1F).
Since the Prx III-dependent release of H2O2 from the mi-
tochondria is not only under the control of the Trx2-Txnrd2
node but can also be altered by grx2 in a glutathione (GSH)-
dependent manner (22), we tested how Txnrd2-deficient cells
would react to an additional loss of GSH. Indeed, when
Txnrd2 - / - cells were treated with L-buthionine sulfoximine
(BSO), a highly specific and irreversible inhibitor of the
GSH-synthesizing enzyme c-glutamylcysteine synthetase,
cell survival and proliferation were considerably impaired
(n = 6, Fig. 1G).
Targeted loss of Txnrd2 substantially impairs
tumor growth in vivo
Having been characterized, transformed cells were sub-
cutaneously implanted into the retral flank of C57BL/6 mice.
Although single cell-derived transformed fibroblasts showed
no difference in proliferation rates in vitro (n = 6, Fig. 1F), the
tumor mass of tumors formed by Txnrd2-deficient cells was
substantially reduced by *50% (mean 0.8 – 0.16 g, median
Innovation
Investigations regarding the role of reactive oxygen
species (ROS) in PHD2 stabilization and thus hypoxia-
inducible factor-1a (Hif-1a) signaling in tumor develop-
ment have yielded controversial results. Taking advantage
of well-defined knockout tumor models, evidence is pro-
vided that the chronic leakage of mitochondrial ROS
triggers PHD2 stabilization in a JNK-dependent manner
that, ultimately, leads to impaired tumor angiogenesis and
tumor growth. This study highlights the relevance of mi-
tochondrial thioredoxin reductase as a yet-unrecognized
critical player in tumor development.
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0.6 g) after 11 days in contrast to tumors from Txnrd2-
expressing cells (mean 1.7 – 0.34 g, median 1.57 g, n = 25,
Fig. 2A). Analysis of tumor growth at different time points
indicated that the difference in the tumor mass was most
pronounced on day 11 (day 2, n = 3; day 3, n = 9; day 4, n = 3;
day 6, n = 9, day 8, n = 3; day 11, n = 25, Fig. 2B).
Histological analysis was performed to elucidate the un-
derlying reasons for the attenuated tumor growth. Quantifi-
cation of cells positive for cleaved caspase-3, an apoptosis
marker, revealed no difference (Txnrd2 + / + 0.08 – 0.1 vs.
Txnrd2 - / - 0.07 – 0.05 positive cells per region of interest,
[Fig. 2C]). The assessment of necrotic areas within the tu-
mors (n = 6) also revealed that the smaller tumor volume was
not a result of necrotic cell loss (percentage of the necrotic
area relative to the entire tumor area: Txnrd2 + / + tumors:
20% – 6.5% vs. Txnrd2 - / - tumors: 14.5% – 7.2%, data not
shown). However, Txnrd2-deficient tumors immunostained
for the proliferation marker Ki-67 showed a significantly lower
ratio of proliferating to nonproliferating cells (proliferation
index [PI]) than WT tumors (0.39 – 0.19 vs. 0.68 – 0.14, n = 6
tumors per group, Fig. 2D).
Txnrd2 - / - tumors are highly susceptible
to pharmacologic GSH deprivation
In our initial in vitro experiments, we could show that
depletion of GSH by BSO resulted in the death of Txnrd2-
deficient cells (Fig. 1G). Since both Txnrd2 and grx2 con-
tribute to the reduction of Prx III (22), thereby controlling
H2O2 emission from the mitochondria, we assessed whether
inhibition of the de novo GSH synthesis may represent a
pharmacological rationale to further reduce the growth of
FIG. 1. Targeted loss of Txnrd2 and its effects on cellular redox balance. (A) Schematic outline of the generation of
the conditional Txnrd2 knockout (KO) allele (10). (B) Expression of Txnrd2 in MEFs was analyzed on the genomic (top
panels), mRNA (middle panels) as well as at the protein level (bottom panels). Equal loading was confirmed by Aldolase or
b-Actin expression.(C) Immunoblot revealed that grx2 expression levels are strongly upregulated in Txnrd2 - / - MEFs. (D)
Total cellular ROS levels were determined by flow cytometry using the fluorogenic probe CellROX Deep Red Reagent.
Note that despite the enhanced levels of grx2 expression, Txnrd2-deficient MEFs accumulate more ROS than wild-type
(WT) cells. (E) Equal expression of c-Myc and Ha-ras in transformed Txnrd2 + / + and Txnrd2 - / - cells was confirmed by
immunoblotting. (F) The proliferation rate of transformed Txnrd2 - / - MEFs (KO) is similar to that of WT cells. (G)
Transformed Txnrd2 - / - cells are sensitive to cell death induced by GSH depletion in contrast to WT cells. Data in (D) are
represented as mean – SD, data in (F, G) as mean – SEM. ***p < 0.001. grx2, glutaredoxin-2; MEFs, mouse embryonic
fibroblasts; ROS, reactive oxygen species; RT-PCR, real-time-polymerase chain reaction; SD, standard deviation.
940 HELLFRITSCH ET AL.
Txnrd2-deficient tumors in vivo. First, we confirmed that
Txnrd2-deficient tumors also expressed significantly higher
levels of grx2 than WT tumors (n = 3 tumors per group, Sup-
plementary Fig. 1A; Supplementary Data are available online
at www.liebertpub.com/ars). Subsequently, BSO was admin-
istered via the drinking water, which proved highly effi-
cient. Glutathione levels dropped sharply, as shown by high-
performance liquid chromatography (HPLC) analysis (Fig. 3A).
Reduced glutathione (GSH) (0.0007 – 0.0002lmol/lg protein)
and oxidized glutathione (GSSG) levels (0.0008 – 0.0003 lmol/
lg protein) were considerably diminished in Txnrd2-deficient
tumors compared with untreated Txnrd2- / - tumors when BSO
was administered via the drinking water (GSH 0.015 – 0.003;
GSSG 0.003 – 0.001lmol/lg protein) (n = 8 tumors per group,
Fig. 3A, B). The decrease of the GSH/GSSG ratio in BSO-
treated Txnrd2 null tumors indicates elevated levels of oxidative
stress (Fig. 3C, n = 8 tumors per group). Most importantly,
manipulation of in vivo glutathione levels by BSO caused a
further reduction of Txnrd2-deficient tumor mass by *38%
(0.52 – 0.14 g) compared with untreated Txnrd2- / - tumors
(0.84 – 0.27 g, n = 8, Fig. 3D).
Loss of Txnrd2 delays the angiogenic switch
and impairs tumor angiogenesis
The tumor-surrounding vascular network of Txnrd2-
deficient tumors was less prominent compared with WT
tumors (Fig. 4A). In line, quantification of tumor vessels
demonstrated significantly fewer vessels per Txnrd2-deficient
tumor (143 – 13.9) compared with WT tumors (239 – 30.43,
n = 6, Fig. 4B).
Reduced expression of key angiogenic players
in tumors derived from Txnrd2 - / - cells
The delayed angiogenic switch and the diminished vascu-
larization could be attributed to a substantial reduction of Hif-
1a protein levels in Txnrd2-deficient tumors (day 3: 38%– 2%;
day 6: 41% – 7%) compared with tumors expressing Txnrd2
(day 3, day 6: arbitrarily set to 100%) at both time points (n = 4
per time point, Fig. 4C). In accordance, vascular endothelial
growth factor A (VEGF-A) levels were also significantly re-
duced at day 3 (18%– 2%) in these tumors compared with
Txnrd2 WT tumors (arbitrarily set to 100%, Fig. 4C). This
phenotype was still present on day 6 of tumor growth
(Txnrd2 + / + : arbitrarily set to 100% vs. Txnrd2- / - : 59% – 2%).
An ELISA specific for mouse VEGF confirmed that Txnrd2-
deficient tumors contained less VEGF-A (n = 4 per time point,
day 3: 0.19 – 0.06 pg/lg protein; day 6: 0.09 – 0.05 pg/lg pro-
tein) than WT tumors (day 3: 0.48 – 0.24 pg/lg protein day 6:
0.12 – 0.05 pg/lg protein) (data not shown).
Hif-1a stabilization in response to serum withdrawal
and hypoxia is impaired
Under normal cell culture conditions, Hif-1a expression
was barely detectable in either cell line (Txnrd2+ / + : arbitrarily
FIG. 2. Loss of Txnrd2 results in a
strong reduction in tumor growth.
(A) Subcutaneous injection of single-
cell-derived transformed cells into
C57BL/6 mice revealed a substantial
reduction of tumor growth in Txnrd2
null tumors. (B) A longitudinal deter-
mination of tumor mass indicated that
tumor weight differences were most
pronounced at day 11. (C, D) While the
number of cells positive for cleaved
caspase-3 (apoptotic cells) was not dif-
ferent among the groups at day 11 (C),
the number of proliferating, Ki-67-
positive cells was strongly reduced in
Txnrd2 null tumors (D). ***p < 0.001
Data are represented as mean – SD. n.s.,
not significant. Scale bar = 100 lm.
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set to 100% vs. Txnrd2- / - : 50% – 16.7%, n = 6, Fig. 4D).
However, Hif-1a expression substantially increased in WT
cells but not in Txnrd2-deficient cells after serum withdrawal
(Txnrd2+ / + : 4830% – 2640% vs. Txnrd2- / - : 70% – 17.3%)
(n = 6, Fig. 4D). A similar effect was also observed under
hypoxic conditions (n = 4, Supplementary Fig. S1C).
To investigate whether Hif-1a is regulated at the transcrip-
tional and/or the translational level, Hif-1a mRNA expression
levels were assessed by quantitative real-time-polymerase
chain reaction (qRT-PCR). Under normal cell culture condi-
tions, Hif-1a mRNA levels were comparable (Txnrd2+ / + :
arbitrarily set to 100% vs. Txnrd2- / - : 110% – 26%, n = 5, data
not shown). Starvation resulted in a moderate increase in WT
cells, whereas Txnrd2-deficient cells failed to upregulate Hif-
1a mRNA levels (Txnrd2+ / + : 190% – 78% vs. Txnrd2- / - :
90% – 35%). These data indicate that stabilization of the ma-
jority of Hif-1a occurs at the protein level since the small
change of Hif-1a transcripts was unlikely to account for the
increased levels of Hif-1a protein in WT cells.
Increased PHD2 expression promotes Hif-1a protein
degradation in Txnrd2 - / - cells and tumors
Next, we examined some upstream regulators of Hif-1a
protein stability, including HIF prolyl hydroxylases. Inter-
estingly, even under baseline conditions, PHD2 protein levels
were elevated in Txnrd2 - / - cells compared with control
cells (Txnrd2 + / + : arbitrarily set to 100% vs. Txnrd2 - / - :
322.2% – 99.8%, n = 4, Fig. 5A). Vice versa, knockdown of
PHD2 using siRNA increased Hif-1a protein levels in both
WT and Txnrd2-deficient MEFs, thereby substantiating that
PHD2 is the main regulator of Hif-1a protein stability (n = 3,
Supplementary Fig. S1D).
Serum starvation had no additional impact on PHD2 pro-
tein expression in either of the cell lines (n = 4, Fig. 5A).
Consistent with these in vitro findings, Txnrd2 null tumors
also displayed augmented PHD2 expression (n = 3, Supple-
mentary Fig. S1B).
To examine whether the mRNA levels were also increased,
we performed qRT-PCR. Indeed, Txnrd2 - / - cells showed
statistically significant enhanced levels of PHD2 mRNA
(n = 11, WT arbitrarily set to 100% vs. KO 242% – 55%, data
not shown).
Apart from affecting Hif-1a stabilization, PHD2 is also a
well-known regulator of nuclear factor-jB (NF-jB) activity
(11). Indeed, immunocytochemistry revealed reduced nu-
clear translocation of the p65 NF-jB subunit in Txnrd2 null
cells (Fig. 5B). Quantification of nuclear translocation of p65
confirmed this observation (n = 6, Fig. 5C).
Enhanced JNK phosphorylation leads to increased
PHD2 protein levels
Intrigued by the findings that Txnrd2 deletion impairs tu-
mor growth via an increase in PHD2 expression, we en-
deavored to unmask a previously unknown link between
Txnrd2 and PHD2. Since JNK is known to be regulated by the
cellular redox status (27), we investigated its phosphorylation
status. Indeed, JNK phosphorylation was increased in im-
mortalized Txnrd2 - / - cells in contrast to their WT coun-
terparts (n = 5, Fig. 6A) and this effect could be attributed
to elevated ROS as the phosphorylation status could be re-
duced by addition of polyethylene glycol-conjugated catalase
(PEG-catalase) (n = 4, Fig. 6B). Substantiating our hypoth-
esis that ROS-induced, sustained JNK activation leads to
elevated PHD2 expression, PEG-catalase treatment also
FIG. 3. Loss of Txnrd2 renders
tumors susceptible to GSH depletion.
(A) Pharmacological glutathione de-
pletion by BSO was confirmed by
HLPC in tumor samples. (B) BSO
treatment efficiently depleted tumors
from glutathione as determined by
measuring the levels of GSSG by
HLPC. (C) The decrease of the GSH/
GSSG ratio in BSO-treated Txnrd2 null
tumors indicates elevated levels of ox-
idative stress. (D) BSO treatment of
tumor-bearing mice via the drinking
water caused a further reduction in
growth of Txnrd2 null tumors. Data in
(A, B) are represented as mean – SD,
data in (C, D) as mean – SEM.
*p < 0.05, ***p < 0.001. BSO, L-
buthionine sulfoximine.
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blunted PHD2 expression (n = 4, Fig. 6B). To provide a
molecular link between mitochondrial ROS and increased
JNK-phosphorylation, we measured PTP activity. ROS have
been implicated in this pathway through inhibition of the
counteracting JNK phosphatases (27), and measurements of
protein tyrosine phosphatase (PTP) activity, indeed, dem-
onstrated a reduced activity in the Txnrd2-deficient cells
(n = 7, Fig. 6F).
To investigate whether the Txnrd2-dependent PHD2
regulation was a general mechanism and not a cell type-
specific effect, we manipulated Txnrd2 expression lev-
els in the murine lung tumor cell line LLC1. Using
endoribonuclease-prepared small interfering RNA (esiR-
NA), we were able to decrease Txnrd2 protein levels
by *90% compared with scrambled esiRNA-treated cells
(n = 4, Fig. 6C). This knockdown led to a subsequent in-
crease in pJNK and PHD2 levels in Txnrd2-deficient LLC1
cells. Furthermore, treating Txnrd2 KO MEFs and LLC1
cells with the JNK inhibitor SP600125 caused both a de-
crease of basal pJNK levels and a strong decrease in PHD2
expression, which is in accordance with the proposed
mechanism (n = 5, Fig. 6D). These data demonstrate that
this Txnrd2-pJNK-PHD2 axis is also a relevant pathway for
bona fide tumor cells. Finally, knockdown of JNK by siRNA
significantly attenuated PHD2 expression (control siRNA
arbitrarily set to 100%, siRNA: JNK 22.6% – 3.7%, PHD2
53.2% – 6.3%, n = 13, exemplarily shown in Fig. 6E), fur-
ther substantiating our findings that JNK acts as an upstream
participant in this pathway.
Expression of Txnrd2 in human cancer tissue
To demonstrate that our findings are also of relevance for
human tumors, the expression of Txnrd2 was studied by
immunohistochemistry in human cancer tissue derived from
three different types of tumors: colon carcinoma (n = 10),
hepatocellular carcinoma (n = 8), as well as lung adenocar-
cinoma (n = 8). In colon carcinomas as well as in hepatocel-
lular carcinomas, we could observe an abundant expression
of Txnrd2. Lung adenocarcinomas also expressed Txnrd2,
however to a much lesser extent than in the colon and liver
samples (Supplementary Fig. S2). These observations are in
line with previously published reports (9, 49) as well as with
the human protein atlas (48).
FIG. 4. Loss of Txnrd2
delays the angiogenic switch
and reduces tumor vascu-
larization. (A) The tumor-
surrounding vascular network
was less prominent in the
Txnrd2 null tumors at 3 days
after tumor inoculation. Dot-
ted circles outline the tumor
tissue. (B) Quantification of
the vessels by CD31 staining
confirmed the morphological
finding illustrated in (A). (C)
Analysis of key-angiogenic
factors revealed decreased
Hif-1a as well as VEGF-A
protein expression in Txnrd2
null tumor tissues at days 3
and 6 of tumor growth. *p <
0.05, **p < 0.01, ***p < 0.001.
Left panel: representative
immunoblots from day 3;
middle and right panels:
semi-quantitative assessment
of immunoblots. (D) Trans-
formed Txnrd2 - / - cells
failed to stabilize Hif-1a pro-
tein after serum starvation.
Left panel: representative im-
munoblot; right panel: semi-
quantitative assessment of
immunoblots. All data are
represented as mean – SD.
Hif-1a, hypoxia-inducible
factor-1a; VEGF-A, vascular
endothelial growth factor A.
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Discussion
Elevated levels of ROS have been detected in almost all
cancers, where they promote many aspects of tumor devel-
opment and progression, including DNA damage, activation
of inflammatory pathways, receptor tyrosine kinase signal-
ing, and stabilization of Hif-1a (30). On the other hand,
several oncogenes were recently discovered to act as active
inducers of NF-E2-related factor-2 (Nrf2), which, in turn,
promotes an ROS detoxification program required for tumor
initiation (13). Moreover, most tumor cells also express in-
creased levels of antioxidants to detoxify ROS, suggesting
that a delicately balanced elevation of intracellular ROS
levels is required for cancer cell function (30, 40).
Since the PrxIII-Trx2-Txnrd2 node is considered the most
important route for mitochondrial H2O2 removal (14, 45) and
we observed an abundant expression of Txnrd2 in a variety of
human tumors (Supplementary Fig. S2), we employed ge-
netically engineered Txnrd2-deficient cells to study the ef-
fects of an altered mitochondrial redox balance on tumor
signaling and growth. Indeed, our model enabled us to unveil
how a chronic change of this balance affects Hif signaling
and tumor growth via a previously unknown pathway. The
cornerstones of this pathway encompass a ROS-dependent
activation of JNK after the loss of Txnrd2, elevated PHD2
protein and mRNA expression, a failure to stabilize Hif-1a in
response to hypoxia and other stressors, and decreased
VEGF-A levels. In vivo we could observe a delayed angio-
genic switch, attenuated tumor vascularization, and, ulti-
mately, reduced growth of tumors lacking Txnrd2.
Unexpectedly and in contrast to previous results (5, 8, 17),
loss of Txnrd2 followed by a compensatory increase in grx2
expression, as well as moderately increased ROS levels, did
not stabilize Hif-1a. Numerous studies have demonstrated
that addition of exogenous ROS leads to the stabilization of
Hif-1a protein and activation of Hif target genes such as
VEGF-A (4, 8, 15). In accordance, tumor cell-derived ROS
can regulate angiogenesis and tumor growth through VEGF
(52) and exposure to antioxidants has been demonstrated to
delay tumorigenesis by reducing HIF levels (16). Given the
previous reports, we expected that the Txnrd2 deletion and
coincident further elevation of ROS levels would lead to a
stabilization of the Hif-1a protein through PHD2 inactiva-
tion; for instance, by oxidizing PHD-bound Fe(II) to Fe(III)
(17, 38), and/or the cysteine residue 201 within the catalytic
domain of PHD2, thereby further inhibiting PHD2 activity
(35, 37). In this study, we observed quite the contrary: Hif-1a
protein levels were reduced not only in Txnrd2 - / - tumors
but also in Txnrd2 - / - MEFs, particularly following certain
stressors such as hypoxia or serum starvation. The diminished
Hif-1a levels could be attributed to high PHD2 expression,
which leads to hydroxylation of key proline residues of Hif-
1a and subsequent targeting of Hif-1a to the proteasome (25,
26). Considering the existing reports in the literature, these
findings indicate that, apparently, PHD2 is differentially
regulated upon a ROS challenge. In contrast to an acute and
FIG. 5. PHD2 protein levels are
highly increased in Txnrd2 null
cells. (A) PHD2 protein levels are
strongly increased in Txnrd2 - / - cells,
both under normal cell culture condi-
tions and in response to starvation. Data
are represented as mean – SEM. (B)
Nuclear translocation of the p65 subunit
of NFjB is diminished in Txnrd2- / -
cells as shown by immunocytochemis-
try. (C) An NFjB-specific transcription
factor assay confirmed the data shown in
(B). *p < 0.05, **p < 0.01, ***p < 0.001.
Data are represented as mean – SD.
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possibly nonphysiological, exogenous bolus administration
of ROS that inhibits PHD2 activity, a compensatory ex-
pression of the mitochondria-located oxidoreductase grx2
is induced in Txnrd2-deficient cells, thereby keeping the
emission of ROS from the mitochondria in a cell-tolerable,
however moderately elevated range. This continuous and
modest elevation of endogenous ROS in Txnrd2-deficient
cells appears to result in an adaptive upregulation of PHD2
protein levels, possibly as a protective measure against
chronically increased Hif-1a expression. A similar adap-
tive mechanism has also been observed during chronic
hypoxia. Acute hypoxia impairs PHD2 activity, whereas
chronic hypoxia inhibits mitochondrial respiration, thus
restoring oxygen availability and leading to PHD2 over-
activation (18).
In pursuit of a molecular link between mitochondrial ROS
and increased PHD2 expression, we investigated the redox-
sensitive JNK signaling pathway. ROS-induced JNK phos-
phorylation via Mitogen-activated protein kinase kinase 4
(MKK4) can be initiated by the liberation of the apoptosis
signal-regulating kinase 1 (ASK-1) from its endogenous
suppressor, reduced thioredoxin 1 (42). Furthermore, ROS
have been implicated in this pathway through inhibition of
JNK phosphatases (27) and we could indeed measure a re-
duced activity of PTPs in the Tnxrd2-deficient cells. Fur-
thermore, we could show that JNK phosphorylation was
markedly increased in Txnrd2 - / - cells as well as in the es-
tablished mouse cancer cell line, LLC1, when Txnrd2 was
knocked down. Administration of the JNK inhibitor
SP600125 and knockdown of JNK by siRNA substantiated
FIG. 6. Deletion of Txnrd2 in-
creases PHD2 expression via sus-
tained JNK phosphorylation. (A)
Representative immunoblot showing
the substantially augmented presence
of phosphorylated JNK (pJNK) in
Txnrd2 null MEFs. (B) PEG-catalase
treatment of Txnrd2 - / - cells not only
lowered the phosphorylation of JNK
but also reduced the overall PHD2
protein levels. (C) Knockdown of
Txnrd2 in the bona fide tumor cell line
LLC1 led to a subsequent increase of
PHD2 and pJNK protein levels. (D)
The JNK inhibitor SP600125 reduced
phosphorylated JNK as well as PHD2
protein levels in both transformed
Txnrd2 - / - cells and the Txnrd2-
deficient tumor cell line, LLC1. (E)
siRNA-mediated knockdown of JNK
in Txnrd2 - / - MEFs also led to a re-
duction in PHD2 expression levels.
(F) PTP-activity is significantly re-
duced in Txnrd2 - / - cells compared
with WT cells. *p < 0.05. JNK, c-Jun
NH2-terminal Kinase; MEFs, mouse
embryonic fibroblasts; PEG-catalase,
polyethylene glycol-conjugated catalase;
PTP, protein tyrosine phosphatase.
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our hypothesized mechanism, as this led to reduced PHD2
protein levels, thus confirming the yet-unrecognized link
between JNK and PHD2 expression. Currently, it remains to
be shown how exactly PHD2 levels are regulated by acti-
vated JNK.
Taken together, our in vitro observations serve as a plau-
sible foundation for the restricted growth of Txnrd2-null tu-
mors. First, JNK signaling has been shown to suppress tumor
growth (33, 50). Second, tumor angiogenesis is, at least
partly, regulated by PHD2 (7), and Txnrd2-null tumors ex-
press reduced Hif-1a as well as reduced VEGF-A protein
levels. Finally, PHD2 has additional Hif-independent tumor
suppressor functions (7), which are also in agreement with
the reduced tumor growth observed in our model.
We previously showed that primary Txnrd2 - / - fibroblasts
are highly sensitive to GSH depletion-induced cell death
(10). As demonstrated here, this apparently also holds true for
immortalized cells and tumors derived thereof, most likely
due to a block of the compensatory GSH-dependent Prx III
reduction by grx2. For future studies targeting antioxidants to
efficiently combat cancer, we therefore suggest the con-
comitant targeting of at least two key antioxidant systems.
In conclusion, our data describe a hitherto unrecognized
pathway for PHD2 activation via JNK, originating from an
altered mitochondrial redox balance. Phosphorylated JNK
leads to a sustained expression of PHD2 in a yet unknown
manner, ultimately leading to the impairment of Hif-1a sig-
naling. While our data oppose previous results on PHD2 in-
hibition by ROS, this should be rationalized on the basis of
variations in the models regarding radicals, sources of ROS,
as well as their concentrations and the duration in which they
are present.
Although our study only scratches the surface regarding
the relevance of Txnrd2 for human cancer biology, we hope it
will motivate other groups to study ROS-controlling systems
in this context. Finally, our findings highlight the need for
future anti-cancer strategies to consider the fine tuning of
intracellular ROS signaling to efficiently shift cells from
ROS-dependent tumor growth-promoting events toward
ROS-induced cell death signaling.
Materials and Methods
Cell lines and reagents
Txnrd2 + / + and Txnrd2 - / - MEFs were isolated from em-
bryos at embryonic day E12.5 from breeding of heterozygous
Txnrd2 mice. Genotyping and cell culturing was performed
as previously described (10). Primer sequences are listed
in Supplementary Tables S1 and S2. Primary MEFs (passage
number < 10) were immortalized by serial passaging (pas-
sage number > 10) as described (39). LLC1 cells were
obtained from ATCC (Teddington, United Kingdom). To
induce Hif-1a protein expression, cells were either cultured
in serum-free medium for 4 h or kept in a hypoxic chamber
(1% O2) for 6 h.
Generation of transformed Txnrd2 + / +
and Txnrd2 - / - cells
For the transformation of cells, MEFs were co-transduced
with c-Myc and Ha-rasV12-expressing lentiviruses as de-
scribed (31). Soft agarose assays were performed to select
successfully transformed cells. After 7 days of growth in soft
agarose, single-cell-derived colonies were isolated, ex-
panded, and analyzed for expression of Txnrd2, c-Myc, and
Ha-rasV12. To assess the efficacy of transformation with
c-Myc and Ha-rasV12, cells were analyzed for green fluo-
rescent protein (GFP) expression using BD FACSort
(Beckton Dickinson, Heidelberg, Germany). Data were an-
alyzed using the CellQuest software (Beckton Dickinson)
and WinMDI software, version 2.9 (Scripps Research In-
stitute, La Jolla, CA).
Proliferation assay
Cell proliferation and cytotoxicity were measured using
the electronic cell sensor array technology xCELLigence
(Roche, Mannheim, Germany) as described (32). BSO (Sigma-
Aldrich, Munich, Germany) was used at a final concentration
of 10 lM to inhibit the de novo synthesis of GSH.
Measurement of cellular ROS levels
ROS generation was assessed using CellROX Deep Red
Reagent (Life Technologies, Darmstadt, Germany) accord-
ing to the manufacturer’s recommendations. Fluorescence
intensity was analyzed by flow cytometry using a Gallios 2/8
flow cytometer (Becton Coulter, Krefeld, Germany) at an
excitation wavelength of 633 nm and emission collected with
a 660 band-pass detector. Cells were gated and analyzed
using the Gallios Data acquisition and analysis software
(Becton Coulter).
Measurement of GSH concentration in cells
and tumors
Total glutathione content in cells was analyzed by per-
forming a modified assay based on a method first described
by Tietze (46). The concentration of total glutathione in cells
was calculated as lM/mg protein and referenced to a 10 mM
GSH calibration solution (Sigma-Aldrich). Reduced and
oxidized glutathione concentrations (GSH and GSSG) in
tumor samples were measured by isocratic HPLC as previ-
ously described (31).
Quantitative real-time PCR
The expression of Hif-1a, PHD2, and Txnrd2 was inves-
tigated by RT-PCR/qRT-PCR as described (31). Expression
was normalized to b-actin or aldolase expression. Primer
sequences are listed in Supplementary Table S2.
Hematoxylin-eosin staining/immunohistochemistry/
immunofluorescence and image analysis
Paraformaldehyde-fixed (4% w/v, in phosphate-buffered
solution [PBS]) and paraffin-embedded tumor material was
cut in 5 lm-thick sections and stained as described (10).
Hematoxylin-eosin (H&E) staining, immunohistochemistry,
and immunofluorescence staining were performed as previ-
ously described (2). Antibodies are listed in Supplementary
Table S3. As control, primary antibodies were omitted during
staining. Slides for peroxidase staining were incubated with
peroxidase-conjugated streptavidin (Vectastain KIT ABC;
Vector Laboratories, Linaris, Wertheim-Bettingen, Ger-
many). Thereafter, slides were incubated with Vector DAB
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kit or AEC kit (Vector Laboratories). Sections were counter-
stained with hematoxylin. Sections for immunofluorescence
were counterstained with 4,6-diamidino-2-phenylindole
([DAPI], Hard Set Mounting Medium; Vector Laboratories).
Immunostaining was analyzed using the Olympus BX41 mi-
croscope in combination with the CAMEDIA C-5050 digital
camera and the software Olympus DP-Soft v3.2 (Olympus,
Tokio, Japan). For the quantification of tumor vascularization,
tumor cell proliferation, tumor cell apoptosis, and necrosis,
three representative sections per tumor were analyzed (n = 6
tumors) and micrographs were obtained from five random re-
gions of interest from all three sections. Altogether, the analysis
of these 15 random microscopic visual fields per tumor was
performed in a blinded fashion by two researchers using a 20 ·
objective. Total blood vessels were determined by counting the
number of CD31-positive blood vessels. Proliferation was
studied by counting Ki-67 positive and -negative cells. The
ratio of proliferative to nonproliferative cells was expressed as
PI. Apoptosis was assessed by counting caspase-3 positive
cells. For the determination of necrosis, the percentage of the
necrotic area relative to the entire tumor area was measured on
H&E stained tumor sections.
Immunoblotting
Immunoblotting was performed as previously described
(1). Primary antibodies are listed in Supplementary Table S4.
Detection of Txnrd2 expression was achieved with a Txnrd2-
specific antibody as described (31). Nuclear translocation of
Hif-1a in cells was analyzed with the NE-PER Nuclear and
Cytoplasmic Extraction Reagent (Fisher Scientific GmbH,
Schwerte, Germany). Equal loading was confirmed with a
lamin-specific antibody. To block H2O2, cells were treated
with PEG-catalase (50 U/ml; Sigma-Aldrich) for 18 h.
To analyze the levels of phosphorylated JNK, samples
were lysed with buffer containing sodium fluoride (0.5 mM)
and Na3VO4 (0.5 mM) (Sigma Aldrich). All blots were
stripped and reprobed with either b-actin or glyceraldehyde
3-phosphate dehydrogenase (GAPDH). To block JNK acti-
vation, the specific JNK-inhibitor SP600125 (#420119,
50 lM; Merck Millipore, Schwalbach, Germany) was applied
to the cell culture medium, either for 8 h or overnight. Ap-
plication of dimethyl sulfoxide (DMSO) served as a control.
PHD2 knockdown in Txnrd2 + / + and Txnrd2 - / - MEFS
MEFs were transfected with siMax siRNA (Eurofins Geno-
mics, Ebersberg, Germany) using the following sequences:
PHD2 siRNA 5¢-GUG GAG GUA UUC UUC GAA UTT-3¢;
scramble siRNA 5¢-UUC UUC GAA CGU GUC ACG UTT-3¢.
105 cells were seeded onto 12-well plates and incubated with
5 nM siRNA and HiPerfect transfection reagent (Qiagen, Hil-
den, Germany) in full medium for 50 h. Subsequently, cells
were washed in PBS and proteins were extracted by cell lysis.
Knockdown of PHD2 was confirmed by immunoblot.
Txnrd2 knockdown in LLC1 tumor cells
LLC1 cells were transfected with MISSION esiRNA
targeting mouse Txnrd2 (EMU067221; Sigma-Aldrich) ac-
cording to the manufacturer’s instructions. Cells were har-
vested, lysed for 72 h after transfection, and blotted against
designated antibodies as described earlier.
JNK knockdown in Txnrd2 - / - MEFs
MEFs were transfected with FlexiTube siRNA (Qiagen)
against both JNK1 (GS26419) and JNK2 (GS26420). Reverse
transfection was performed in 24-well plates according to the
manufacturer’s advice using 5 ll HiPerFect transfection re-
agent and 50 nM siRNA for 70,000 cells for 72 h. Subse-
quently, cells were lysed and knockdown of JNK was
confirmed by immunoblot.
Enzyme-linked immunosorbent assay
To measure mouse VEGF in cell culture supernatants and
tumor tissue, the Mouse VEGF Quantikine Immunoassay
(R&D Systems, Wiesbaden-Nordenstedt, Germany) was
employed according to the manufacturer’s recommendations.
Absorbance was measured at a wavelength of 450 nm using
the ELISA plate reader Infinite F200 (Tecan, Crailsheim,
Germany). Total protein concentration in supernatants and
tumor homogenates was measured with the BCA Protein
Assay Kit (Pierce; Fisher Scientific).
Subcutaneous xenograft tumor model
Transformed Txnrd2- / - and Txnrd2+ / + cells (4 · 106 cells
dissolved in 200 ll sterile PBS) were injected subcutaneously
into the retral flank of C57BL/6 mice. Tumors were collected
over a period of 11 days. All animal experiments were per-
formed in compliance with the German Animal Welfare Law
and had been approved by the institutional committee on ani-
mal experimentation and the government of Upper Bavaria.
Treatment of tumor-bearing mice with BSO
For the in vivo pharmacological studies, 4 · 106 transformed
Txnrd2-deficient cells in 200 ll sterile PBS were injected sub-
cutaneously into the retral flank of C57BL/6 mice. Tumors were
allowed to settle for 3 days. From day 3 onward, BSO (20 mM)
was administered via the drinking water for 8 days. BSO-
containing water was exchanged every third day. At day 11,
mice were sacrificed and tumor mass and volume was analyzed.
Measurement of PTP activity
PTP activity in total cell lysates was measured toward a
32P-labeled phosphotyrosine substrate (AEEEIpYGEFEA
KKKK) as previously described (43). WT and Txnrd2 - / -
fibroblasts were starved overnight in phenol-red free DMEM
(Gibco, Stockholm, Sweden) with 1% fetal calf serum. Cells
were washed in 20 mM Hepes pH 7.4 (Sigma-Aldrich, Stock-
holm, Sweden) and lysed in degassed lysis buffer (50 mM so-
dium acetate, 150 mM NaCl, 1% NP-40, 25 lg/ml aprotinin,
25 lg/ml leupeptin, 250 U/ml catalase, and 125 U/ml super-
oxide dismutase [Calbiochem, Solna, Sweden]). Lysates were
cleared by centrifugation at 21,000 g at 4C for 5 min. A
fraction of the lysate was mixed with deoxygenated 25 mM
imidazole pH 7.4 (Sigma-Aldrich), the PTP substrate (kind gift
from Carl Henrik Heldin) was added, and the mixture was
incubated for 20 min. The dephosphorylation reaction was
stopped by addition of a charcoal mixture (0.9M HCl, 90 mM
sodium pyrophosphate, 2 mM NaH2PO4, 4% vol/vol NoritA;
Sigma-Aldrich) and centrifuged at 21,000 g for 3 min. The
supernatant containing released 32P (PerkinElmer, Upplands
Väsby, Sweden) was transferred to scintillation vials (Sigma-
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Aldrich) with EcoScint A (National Diagnostics, BioNordika,
Stockholm, Sweden), and radioactivity was measured using a
Wallac Winspectral 1414 Liquid Scintillation Counter (Per-
kinElmer). The radioactive signal reflects the activity of the
reduced PTPs and was normalized toward cell lysate treated
with the reducing agent dithiothreitol (DTT; Sigma-Aldrich)
that represents the maximal activity when all PTPs are reduced.
Determination of NFjB activation
Translocation of the NFjB subunit p65 to the nucleus was
analyzed by immunocytochemistry in formaldehyde-fixed
MEFs as described (3). In brief, cells were grown to *80%
confluence on glass coverslips coated with collagen G (10 lg/
ml; Biochrom AG, Berlin, Germany). Subsequently, cells
were fixed with 3.7% formaldehyde, permeabilized with
0.3% Triton X-100, and incubated with a p65-specific anti-
body. Slides were mounted with DAPI-containing Hard Set
Mounting Medium (Vector Laboratories) and analyzed using
the confocal laser scanning microscope Leica TCS SP5
(Leica Microsystems, Wetzlar, Germany).
To further substantiate the results from immunocyto-
chemistry, activation of the NFjB subunit p65 was measured
using the colorimetric NFjB p65 EZ-TFA transcription
factor assay according to the manufacturer’s instructions
(Millipore GmbH, Schwalbach, Germany).
Statistical analysis
Statistical analysis was performed using SigmaPlotª 11.0
software ( Jandel GmbH, Erkrath, Germany). Experimental
values are expressed as mean – standard deviation, unless
stated otherwise. Numbers of independent experiments are
indicated in the corresponding results section. Statistically
significant differences between groups were calculated by
Student’s t-test or analysis of variance followed by Bonfer-
roni’s correction. Non-Gaussian distributed data were ana-
lyzed by the nonparametric Kruskal–Wallis test for nonpaired
data. p < 0.05 was considered significant.
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